This ‘Age-related Macular Degeneration (AMD)-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The age-related macular degeneration market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM age-related macular degeneration market size from 2019 to 2032. The Report also covers current age-related macular degeneration treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed communities. It is an eye disease of elderly individuals that causes a progressive loss of the central vision needed to drive, read, recognize faces, and see the world in color. AMD's progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life. Although AMD's exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD.
AMD is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. AMD can be classified as early, intermediate, or late based on its clinical features, including drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).
AMD can also be characterized as either dry (atrophic or non-neovascular) or wet (exudative or neovascular).
People rarely lose all of their vision from age-related macular degeneration. Their central vision might be bad, but they're still able to do many normal daily activities. Usually, patient are also able to use peripheral vision.
The dry age-related macular degeneration (dAMD) tends to get worse slowly. There is no cure for macular degeneration. Treatment may slow it down or keep the loss of vision. A large number of studies found have shown, that people with dry AMD could slow the disease by taking supplements of vitamins C and E, lutein, zeaxanthin, zinc, and copper.
Wet age-related macular degeneration (wAMD) can be treated with injections of angiogenesis inhibitors into the eye, photodynamic therapy, or laser surgery. None of these treatments will cure wAMD, but each may slow the vision decline rate or stop further vision loss. However, the disease and loss of vision may also progress despite treatment.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases AMD, diagnosed prevalent cases of AMD, type-specific cases of AMD (Dry AMD, and Wet AMD), total age-specific cases of AMD (Dry AMD and Wet AMD), total diagnosed dry AMD cases by stages, and total geographic atrophy cases by visual impairment in the scenario of Age-related Macular Degeneration in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
The epidemiology segment also provides the Age-related Macular Degeneration epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Age-related Macular Degeneration report encloses the detailed analysis of Age-related Macular Degeneration marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Age-related Macular Degeneration clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Eylea (aflibercept): Regeneron Pharmaceuticals
Eylea developed by Regeneron is used to treat wet-AMD. It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Eylea is the brand name for the drug called aflibercept. VEGF, a naturally occurring protein in the body triggers angiogenesis, however, in wet-AMD it is associated with abnormal blood vessel growth which causes edema leading to vision loss. Eylea blocks the growth of abnormal blood vessels in the back of the eye.
At present Regeneron is conducting phase III trials to explore less frequent dosing intervals of Eylea. It is evaluating the drug for a higher dose of 8mg in wet-AMD patients after phase II trials met its primary endpoint.
Beovu (brolucizumab): Novartis
Beovu (brolucizumab) is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.
Beovu is the first FDA-approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.
Lucentis (ranibizumab): Roche
Lucentis (ranibizumab) is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Lucentis is the brand name for the drug, which is called ranibizumab. Ranibizumab is a humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms (e.g. VEGF110, VEGF121, and VEGF165), thereby preventing the binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2
OPT-302: Opthea Limited
OPT-302 (sVEGFR-3) is the first ‘Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. The company is currently conducting two concurrent Phase III clinical trials of OPT-302 for the treatment of wet AMD.
KSI-301: Kodiak Sciences Inc.
KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.The drug is currently being evaluated in Phase III. The readouts of the trial are expected in quarter one of 2023.
RGX-314: Regenxbio
RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. It is a potential one-time gene therapy for the treatment of wet AMD, diabetic retinopathy (DR) and other chronic retinal diseases.RGX-314 is currently being evaluated in patients with wAMD in Phase II and II/III clinical trials.
Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
Danicopan (ALXN2040) is an oral drug developed by Alexion. It is an investigational first-in-class small-molecule inhibitor of factor D, an essential enzyme of the complement alternative pathway, which, when dysregulated, is implicated in the pathogenesis of AMD.The company is conducting a Phase II study in patients with GA secondary to AMD, and data is expected in 2023 plus.
EG-301: Evergreen Therapeutics
EG-301 is an oral dosage form that is effective and safe in animal studies with fewer side effects and is used to treat patients over 50 years of age with dry macular disease. The company is currently conducting a Phase II study to treat non-exudative (dry) AMD.
Age-related Macular Degeneration (AMD) is a chronic, progressive, and severe disease of the central retina and is the main cause of irreversible blindness in the Western world and Asia-Pacific countries. Up to date, 8.7% of the worldwide population has AMD. The wet form of the disease is responsible for more than 90% of the severe central visual acuity (VA) loss associated with AMD.
The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function. In the past years, anti-VEGF injections have become the standard treatment for wet AMD, accounting for better results than the previous choices, such as photodynamic therapy (PDT) and laser photocoagulation. Currently, drugs like Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab), work well to achieve a rapid resolution of exudative signs in most patients. Faricimab and Susvimo have also been recently approved for the treatment of Wet AMD.
At present, the therapeutic landscape of dry AMD is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of dry AMD is poorly understood. However, there are chances of failure to reach the primary outcomes that might be linked to the advanced stage of the disease rather than a lack of action on appropriate targets.
The forecast model does not include other therapy options since the analysis does not consider procedures and lifestyle management therapy options for predicting the market size in the 7MM countries. The market size solely focuses on the revenue generated by the pharmacological treatment of metal poisoning.
This section provides the total Age-related Macular Degeneration market size and market size by therapies in the United States.
The total Age-related Macular Degeneration market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Age-related Macular Degeneration market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the Age-related Macular Degeneration market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Age-related Macular Degeneration market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Age-related Macular Degeneration emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
The publisher performs competitively and market Intelligence analysis of the Age-related Macular Degeneration market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
The age-related macular degeneration market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM age-related macular degeneration market size from 2019 to 2032. The Report also covers current age-related macular degeneration treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Age-related Macular Degeneration: Disease Understanding and Treatment Algorithm
Age-related Macular Degeneration Overview
Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed communities. It is an eye disease of elderly individuals that causes a progressive loss of the central vision needed to drive, read, recognize faces, and see the world in color. AMD's progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life. Although AMD's exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD.
AMD is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. AMD can be classified as early, intermediate, or late based on its clinical features, including drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).
AMD can also be characterized as either dry (atrophic or non-neovascular) or wet (exudative or neovascular).
Age-related Macular Degeneration Diagnosis
AMD rarely causes symptoms in its early stages, annual eye examinations are key to detecting the disease and starting treatments when they are most effective. During an eye exam, the eye healthcare provider checks for changes to the retina and macula. Patients may get one or more of these tests:
- Visual field test: An Amsler grid has a grid of straight lines with a large dot in the center. The healthcare provider asks to identify lines or sections on the grid that look blurry, wavy, or broken. A lot of distortion may indicate that patient have AMD or the disease is worsening. Patient can use this visual field test at home to monitor vision.
- Dilated eye exam: Eye drops dilate, or widen, patient pupils. Once patient's eyes are dilated, healthcare provider uses a special lens to look inside patient's eyes.
- Fluorescein angiography (FA): Healthcare provider injects a yellow dye called fluorescein into a vein in patient's arm. A special camera tracks the dye as it travels through blood vessels in the eye. The photos can reveal any leakage under the macula.
- Optical coherence tomography (OCT): This imaging machine takes detailed images of the back of the eye, including the retina and macula. Optical coherence tomography isn't invasive or painful. Patient simply look into a lens while the machine takes pictures.
- Optical coherence tomography angiography (OCTA): This diagnostic tool uses laser light reflection (instead of fluorescein dye) and the OCT scanning device. It takes just a few moments and produces 3D images of blood flow through the eye.
Age-related Macular Degeneration Treatment
People rarely lose all of their vision from age-related macular degeneration. Their central vision might be bad, but they're still able to do many normal daily activities. Usually, patient are also able to use peripheral vision.
The dry age-related macular degeneration (dAMD) tends to get worse slowly. There is no cure for macular degeneration. Treatment may slow it down or keep the loss of vision. A large number of studies found have shown, that people with dry AMD could slow the disease by taking supplements of vitamins C and E, lutein, zeaxanthin, zinc, and copper.
Wet age-related macular degeneration (wAMD) can be treated with injections of angiogenesis inhibitors into the eye, photodynamic therapy, or laser surgery. None of these treatments will cure wAMD, but each may slow the vision decline rate or stop further vision loss. However, the disease and loss of vision may also progress despite treatment.
Age-related Macular Degeneration Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases AMD, diagnosed prevalent cases of AMD, type-specific cases of AMD (Dry AMD, and Wet AMD), total age-specific cases of AMD (Dry AMD and Wet AMD), total diagnosed dry AMD cases by stages, and total geographic atrophy cases by visual impairment in the scenario of Age-related Macular Degeneration in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Key Findings
- In the year 2021, the total prevalent cases of AMD were approximately 51,743,361 in the 7MM, which might increase at a CAGR of 1.6% by 2032.
- The US accounted for approximately 17,282,569 prevalent cases of AMD in the year 2021.
- In EU-5 countries the highest number of prevalent cases of AMD was observed in Germany with 7,850,793 cases in the year 2021, followed by France.
- Among the 7MM, Japan accounted for approximately 21% prevalent cases of AMD in the year 2021.
- In the year 2021, the total diagnosed cases of AMD were approximately 38,807,521 cases in the 7MM. The highest number of cases were diagnosed in the US.
- In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple number of folds by 2032.
- In the epidemiology model, the total age-specific cases of AMD (Dry-AMD, and Wet-AMD), are divided into age group 50-59 years, 60-69 years, 70-79 years, and ≥80 years respectively. As per the estimates by the publisher, the total age-specific cases of AMD are expected to increase during the forecasted period of 2022-2032.
- In the US, the total diagnosed cases of dry AMD by age distribution were 2,175,435; 3,380,209; 3,495,783; and 2,614,307 cases for the age group 50-59 years, 60-69 years, 70-79 years, and ≥ 80 years in 2021.
- In the US, the total diagnosed cases of dry AMD by stages were approximately 10,499,160 cases for early and intermediate dry AMD and 1,166,573 cases for advanced (geographic atrophy associated with dry AMD) in 2021. As per the analysis, stage-wise cases are also expected to by 2032.
- In the US, the total geographic atrophy cases by visual impairment were 349,972; 583,287; and 233,315 cases for mild, moderate to severe, and patients going for surgery or having legal blindness, respectively, in 2021.
Age-related Macular Degeneration Epidemiology
The epidemiology segment also provides the Age-related Macular Degeneration epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Age-related Macular Degeneration Drug Chapters
The drug chapter segment of the Age-related Macular Degeneration report encloses the detailed analysis of Age-related Macular Degeneration marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Age-related Macular Degeneration clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Age-related Macular Degeneration Marketed Drugs
Eylea (aflibercept): Regeneron Pharmaceuticals
Eylea developed by Regeneron is used to treat wet-AMD. It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Eylea is the brand name for the drug called aflibercept. VEGF, a naturally occurring protein in the body triggers angiogenesis, however, in wet-AMD it is associated with abnormal blood vessel growth which causes edema leading to vision loss. Eylea blocks the growth of abnormal blood vessels in the back of the eye.
At present Regeneron is conducting phase III trials to explore less frequent dosing intervals of Eylea. It is evaluating the drug for a higher dose of 8mg in wet-AMD patients after phase II trials met its primary endpoint.
Beovu (brolucizumab): Novartis
Beovu (brolucizumab) is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.
Beovu is the first FDA-approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase with uncompromised efficacy.
Lucentis (ranibizumab): Roche
Lucentis (ranibizumab) is a drug used to treat wet age-related macular degeneration (AMD). It is also used to treat diabetic eye disease and other problems of the retina. It is injected into the eye to help slow vision loss from these diseases. Lucentis is the brand name for the drug, which is called ranibizumab. Ranibizumab is a humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms (e.g. VEGF110, VEGF121, and VEGF165), thereby preventing the binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2
Age-related Macular Degeneration Emerging Drugs
OPT-302: Opthea Limited
OPT-302 (sVEGFR-3) is the first ‘Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. The company is currently conducting two concurrent Phase III clinical trials of OPT-302 for the treatment of wet AMD.
KSI-301: Kodiak Sciences Inc.
KSI-301 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes.The drug is currently being evaluated in Phase III. The readouts of the trial are expected in quarter one of 2023.
RGX-314: Regenxbio
RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. It is a potential one-time gene therapy for the treatment of wet AMD, diabetic retinopathy (DR) and other chronic retinal diseases.RGX-314 is currently being evaluated in patients with wAMD in Phase II and II/III clinical trials.
Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
Danicopan (ALXN2040) is an oral drug developed by Alexion. It is an investigational first-in-class small-molecule inhibitor of factor D, an essential enzyme of the complement alternative pathway, which, when dysregulated, is implicated in the pathogenesis of AMD.The company is conducting a Phase II study in patients with GA secondary to AMD, and data is expected in 2023 plus.
EG-301: Evergreen Therapeutics
EG-301 is an oral dosage form that is effective and safe in animal studies with fewer side effects and is used to treat patients over 50 years of age with dry macular disease. The company is currently conducting a Phase II study to treat non-exudative (dry) AMD.
Age-related Macular Degeneration Market Outlook
Age-related Macular Degeneration (AMD) is a chronic, progressive, and severe disease of the central retina and is the main cause of irreversible blindness in the Western world and Asia-Pacific countries. Up to date, 8.7% of the worldwide population has AMD. The wet form of the disease is responsible for more than 90% of the severe central visual acuity (VA) loss associated with AMD.
Wet AMD Market Outlook
The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function. In the past years, anti-VEGF injections have become the standard treatment for wet AMD, accounting for better results than the previous choices, such as photodynamic therapy (PDT) and laser photocoagulation. Currently, drugs like Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab), work well to achieve a rapid resolution of exudative signs in most patients. Faricimab and Susvimo have also been recently approved for the treatment of Wet AMD.
Dry AMD Market Outlook
At present, the therapeutic landscape of dry AMD is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of dry AMD is poorly understood. However, there are chances of failure to reach the primary outcomes that might be linked to the advanced stage of the disease rather than a lack of action on appropriate targets.
The forecast model does not include other therapy options since the analysis does not consider procedures and lifestyle management therapy options for predicting the market size in the 7MM countries. The market size solely focuses on the revenue generated by the pharmacological treatment of metal poisoning.
The United States Market Outlook
This section provides the total Age-related Macular Degeneration market size and market size by therapies in the United States.
EU-5 Market Outlook
The total Age-related Macular Degeneration market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Age-related Macular Degeneration market size and market size by therapies in Japan are provided.
Age-related Macular Degeneration Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Age-related Macular Degeneration market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Age-related Macular Degeneration market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Age-related Macular Degeneration Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Age-related Macular Degeneration emerging therapies.
Reimbursement Scenario in Age-related Macular Degeneration
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
The publisher performs competitively and market Intelligence analysis of the Age-related Macular Degeneration market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Age-related Macular Degeneration, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Age-related Macular Degeneration epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Age-related Macular Degeneration is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Age-related Macular Degeneration market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Age-related Macular Degeneration market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Age-related Macular Degeneration market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Age-related Macular Degeneration R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Age-related Macular Degeneration. The launch of emerging therapies will significantly impact the Age-related Macular Degeneration market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Age-related Macular Degeneration Report Insights
- Patient Population
- Therapeutic Approaches
- Age-related Macular Degeneration Pipeline Analysis
- Age-related Macular Degeneration Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Age-related Macular Degeneration Report Key Strengths
- 11-Years Forecast
- The 7MM Coverage
- Age-related Macular Degeneration Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Age-related Macular Degeneration Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions Answered
Market Insights:
- What was the Age-related Macular Degeneration market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Age-related Macular Degeneration total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Age-related Macular Degeneration market size during the forecast period (2022-2032)?
- At what CAGR, the Age-related Macular Degeneration market is expected to grow at the 7MM level during the forecast period (2022-2032)?
- What would be the Age-related Macular Degeneration market outlook across the 7MM during the forecast period (2022-2032)?
- What would be the Age-related Macular Degeneration market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden, and unmet needs of Age-related Macular Degeneration?
- What is the historical Age-related Macular Degeneration patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Age-related Macular Degeneration at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Age-related Macular Degeneration?
- Out of the above-mentioned countries, which country would have the highest population of Age-related Macular Degeneration during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Age-related Macular Degeneration along with the approved therapy?
- What are the current treatment guidelines for the treatment of Age-related Macular Degeneration in the US and Europe?
- What are the Age-related Macular Degeneration marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Age-related Macular Degeneration?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Age-related Macular Degeneration?
- What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Age-related Macular Degeneration therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Age-related Macular Degeneration and their status?
- What are the key designations that have been granted for the emerging therapies for Age-related Macular Degeneration?
- What are the 7MM historical and forecasted market of Age-related Macular Degeneration?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving Age-related Macular Degeneration.
- To understand the future market competition in the Age-related Macular Degeneration market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Age-related Macular Degeneration in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Age-related Macular Degeneration market.
- To understand the future market competition in the Age-related Macular Degeneration market.
Table of Contents
1. Key Insights2. Report Introduction
3. Wet AMD Market Overview at a Glance
3.1. Market Share (%) Distribution of Wet AMD by Therapies in 2019
3.2. Market Share (%) Distribution of Wet AMD by Therapies in 2032
4. Dry AMD Market Overview at a Glance
4.1. Market Share (%) Distribution of Dry AMD by Therapies in 2023
4.2. Market Share (%) Distribution of Dry AMD by Therapies in 2032
5. Wet AMD Market: Future Perspective
6. Executive Summary
6.1. Wet AMD
6.2. Dry AMD
7. Key Events
8. Disease Background and Overview
8.1. Introduction
8.1.1. Classification and Clinical Manifestation
8.1.2. Signs and Symptoms of AMD
8.1.3. Risk Factors
8.1.4. Pathophysiology of AMD
8.2. Diagnosis
8.3. Diagnostic Guidelines
8.3.1. NICE Guidelines
8.3.2. American Academy of Ophthalmology
8.3.3. Harvard Ophthalmology
8.3.4. European Society of Retina Specialists (EURETINA)
8.4. Treatment
8.5. Treatment Guidelines
8.5.1. Harvard Ophthalmology
8.5.2. American Academy of Ophthalmology
8.5.3. European Society of Retina Specialists (EURETINA).
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: 7MM
9.2.1. Prevalent Cases of AMD
9.2.2. Diagnosed Prevalent Cases of AMD
9.2.3. Type-specific cases of AMD
9.2.4. Age-specific Cases of AMD
9.2.5. Dry AMD Cases by Stage
9.2.6. Geographic Atrophy (GA) Cases by Visual Impairment (%)
9.2.7. Treatable Cases of AMD
9.3. Total Prevalent Cases of AMD in the 7MM
9.4. Type-specific Diagnosed Prevalent Cases of AMD in the 7MM
9.5. The United States
9.5.1. Total Prevalent Cases of AMD
9.5.2. Total Diagnosed Cases of AMD
9.5.3. Type-specific Cases of AMD
9.5.4. Total Age-specific Cases of AMD
9.5.5. Total Diagnosed Dry AMD Cases by Stages in the US
9.5.6. Total Geographic Atrophy Cases by Visual Impairment in the US
9.6. EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
9.6.1. Germany
9.6.1.1. Total Prevalent Cases of AMD
9.6.1.2. Total Diagnosed Cases of AMD
9.6.1.3. Type-specific Cases of AMD
9.6.1.4. Total Age-specific Cases of AMD
9.6.1.5. Total Diagnosed Dry AMD Cases by Stage
9.6.1.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.2. France
9.6.2.1. Total Prevalent Cases of AMD
9.6.2.2. Total Diagnosed Cases of AMD
9.6.2.3. Type-specific Cases of AMD
9.6.2.4. Total Age-specific Cases of AMD
9.6.2.5. Total Diagnosed Dry AMD Cases by Stage
9.6.2.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.3. Italy
9.6.3.1. Total Prevalent Cases of AMD
9.6.3.2. Total Diagnosed Cases of AMD
9.6.3.3. Type-specific Cases of AMD
9.6.3.4. Total Age-specific Cases of AMD
9.6.3.5. Total Diagnosed Dry AMD Cases by Stage
9.6.3.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.4. Spain
9.6.4.1. Total Prevalent Cases of AMD
9.6.4.2. Total Diagnosed Cases of AMD
9.6.4.3. Type-specific Cases of AMD
9.6.4.4. Total Age-specific Cases of AMD
9.6.4.5. Total Diagnosed Dry AMD Cases by Stage
9.6.4.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.5. The United Kingdom
9.6.5.1. Total Prevalent Cases of AMD
9.6.5.2. Total Diagnosed Cases of AMD
9.6.5.3. Type-specific Cases of AMD
9.6.5.4. Total Age-specific Cases of AMD
9.6.5.5. Total Diagnosed Dry AMD Cases by Stage
9.6.5.6. Total Geographic Atrophy Cases by Visual Impairment
9.7. Japan
9.7.1. Total Prevalent Cases of AMD
9.7.2. Total Diagnosed Cases of AMD
9.7.3. Type-specific Cases of AMD
9.7.4. Total Age-specific Cases of Wet AMD
9.7.5. Total Diagnosed Dry AMD Cases by Stages in Japan
9.7.6. Total Geographic Atrophy Cases by Visual Impairment Japan
10. Patient Journey
11. Marketed Drugs
11.1. Marketed Key cross
11.2. Eylea (aflibercept): Regeneron Pharmaceuticals
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Research and Development
11.2.4. Clinical Development
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Beovu(brolucizumab): Novartis
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Product Profile
11.4. Lucentis (ranibizumab): Roche
11.4.1. Product Description
11.4.2. Regulatory Milestones
11.4.3. Research and Development
11.4.4. Clinical Development
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. Vabysmo (faricimab): Roche
11.5.1. Product Description
11.5.2. Regulatory Milestones
11.5.3. Clinical Development
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.6. Susvimo (ranibizumab): Roche
11.6.1. Product Description
11.6.2. Regulatory Milestones
11.6.3. Clinical Development
11.6.4. Safety and Efficacy
11.6.5. Product Profile
12. Emerging Drugs of Wet AMD
12.1. Key Competitors
12.2. OPT-302: Opthea Limited
12.2.1. Product Description
12.2.2. Other Development Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.2.6. Analysts' Views
12.3. KSI-301: Kodiak Sciences Inc.
12.3.1. Product Description
12.3.2. Other Development Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.3.6. Analysts' Views
12.4. RGX-314: REGENXBIO
12.4.1. Product Description
12.4.2. Other Development Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
12.4.6. Analysts' Views
12.5. AKST4290: Alkahest Inc
12.5.1. Product Description
12.5.2. Other Development Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.5.6. Analysts' Views
12.6. GB-102 (Sunitinib Malate): Graybug Vision
12.6.1. Product Description
12.6.2. Other Development Activities
12.6.3. Clinical Development
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.6.6. Analysts' Views
12.7. RBM-007: Ribomic USA Inc
12.7.1. Product Description
12.7.2. Other Development Activities
12.7.3. Clinical Development
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.7.6. Analysts' Views
12.8. Lytenava (Bevacizumab-vikg): Outlook Therapeutics, Inc.
12.8.1. Drug Description
12.8.2. Other Development Information
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.8.6. Analysts' Views
12.9. UBX1325: Unity Biotechnology, Inc
12.9.1. Drug Description
12.9.2. Clinical Development
12.9.3. Safety and Efficacy
12.9.4. Product Profile
12.9.5. Analysts' Views
12.10. PAN-90806: PanOptica, Inc.
12.10.1. Product Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Development
12.10.4. Safety and Efficacy
12.10.5. Product Profile
12.10.6. Analysts' Views
12.11. CLS-AX (Axitinib): Clearside Biomedical
12.11.1. Product Description
12.11.2. Clinical Development
12.11.3. Safety and Efficacy
12.11.4. Product Profile
12.11.5. Analysts' Views
13. Emerging Drugs of Dry AMD
13.1. Key Cross Competition
13.2. Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
13.2.1. Product Description
13.2.2. Other Development Activities
13.2.3. Clinical Development
13.2.4. Clinical Trial Information
13.2.5. Product Profile
13.2.6. Analysts' Views
13.3. EG-301: Evergreen Therapeutics
13.3.1. Product Description
13.3.2. Clinical Development
13.3.3. Clinical trials Information
13.3.4. Product description
13.3.5. Analysts' Views
13.4. RG6147 (RO7171009): Roche (Genentech)
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Clinical Trials Information
13.4.5. Safety and Efficacy
13.4.6. Product Profile
13.4.7. Analysts' Views
13.5. ALK-001: Alkeus Pharmaceuticals
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Product Profile
13.5.6. Analysts' Views
13.6. Elamipretide: Stealth BioTherapeutics
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Clinical Trials Information
13.6.5. Safety and Efficacy
13.6.6. Product Profile
13.6.7. Analysts' Views
13.7. OpRegen: CellCure Neurosciences
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Clinical Trials Information
13.7.5. Safety and Efficacy
13.7.6. Product Profile
13.7.7. Analysts' Views
13.8. CPCB-RPE1: Regenerative Patch Technologies
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Clinical Trials Information
13.8.5. Safety and Efficacy
13.8.6. Product Profile
13.8.7. Analysts' Views
13.9. Luminate (Risuteganib): Allegro Ophthalmics
13.9.1. Product Description
13.9.2. Other Development Activities
13.9.3. Clinical Development
13.9.4. Clinical Trials Information
13.9.5. Safety and Efficacy
13.9.6. Product Profile
13.9.7. Analysts' Views
13.10. ANX007: Annexon Biosciences
13.10.1. Product Description
13.10.2. Other Development Activities
13.10.3. Clinical Development
13.10.4. Clinical Trials Information
13.10.5. Product Profile
13.10.6. Analysts' Views
13.11. NGM621: NGM Biopharmaceuticals
13.11.1. Product Description
13.11.2. Other Development Activities
13.11.3. Clinical Development
13.11.4. Clinical Trials Information
13.11.5. Safety and Efficacy
13.11.6. Product Profile
13.11.7. Analysts' Views
13.12. LNP023 (Iptacopan): Novartis
13.12.1. Product Description
13.12.2. Clinical Development
13.12.3. Clinical Trials Information
13.12.4. Product Profile
13.12.5. Analysts' Views
13.13. IONIS-FB-LRx: Ionis Pharmaceuticals
13.13.1. Product Description
13.13.2. Other Development Activities
13.13.3. Clinical Development
13.13.4. Clinical Trials Information
13.13.5. Product Profile
13.13.6. Analysts' Views
13.14. Pegcetacoplan: Apellis Pharmaceuticals
13.14.1. Product Description
13.14.2. Other Development Activities
13.14.3. Clinical Development
13.14.4. Clinical Trials Information
13.14.5. Safety and Efficacy
13.14.6. Product Profile
13.14.7. Analysts' Views
13.15. Zimura (Avacincaptad Pegol): Iveric Bio
13.15.1. Product Description
13.15.2. Other Developmental Activities
13.15.3. Clinical Development
13.15.4. Clinical Trials Information
13.15.5. Safety and Efficacy
13.15.6. Product Profile
13.15.7. Analysts' Views
13.16. GT005: Gyroscope Therapeutics and Novartis
13.16.1. Product Description
13.16.2. Other Developmental Activities
13.16.3. Clinical Development
13.16.4. Clinical Trials Information
13.16.5. Safety and Efficacy
13.16.6. Product Profile
13.16.7. Analysts' Views
13.17. RPESC-RPE-4W: Luxa Biotechnology
13.17.1. Product Description
13.17.2. Clinical Developmental
13.17.3. Clinical Trials Information
13.17.4. Product Profile
13.17.5. Analysts' Views
13.18. GEM103: Gemini Therapeutics
13.18.1. Product Description
13.18.2. Other Development Activities
13.18.3. Clinical Development
13.18.4. Clinical Trials Information
13.18.5. Safety and Efficacy
13.18.6. Product Profile
13.18.7. Analysts' Views
14. AMD: Seven Major Market Analysis
14.1. Key Findings
14.1.1. Key Findings of Wet AMD
14.1.2. Key Findings of Dry AMD
14.2. Methodology of AMD
14.3. Market Outlook
14.3.1. Wet AMD Market Outlook
14.3.2. Dry AMD Market Outlook
14.4. Potential of Current and Emerging Therapies of Wet AMD
14.5. Potential of Current and Emerging Therapies of Dry AMD
14.6. Key Market Forecast Assumptions
14.6.1. Key Market Forecast Assumptions of Wet AMD
14.6.2. Key Market Forecast Assumptions
14.7. Attribute Analysis
14.7.1. Attribute Analysis of Wet AMD
14.7.2. Attribute Analysis of Dry AMD
14.8. Market Size of AMD in the 7MM
14.8.1. Market Size of Wet AMD in the 7MM
14.8.1.1. Total Market Size of Wet AMD in the 7MM
14.8.1.2. Total Market Size of Wet AMD by Therapies in the 7MM
14.8.2. Market Size of Dry AMD in the 7MM
14.8.2.1. Total Market Size of Dry AMD in the 7MM
14.8.2.2. Total Market Size of Dry AMD by Therapies in the 7MM
14.9. Market Size of AMD in the United States
14.9.1. Market Size of Wet AMD in the US
14.9.1.1. Total Market Size of Wet AMD in the US
14.9.1.2. Total Market Size of Wet AMD by Therapies in the US
14.9.2. Market Size of Dry AMD in the US
14.9.2.1. Total Market Size of Dry AMD in the US
14.9.2.2. Total Market Size of Dry AMD by Therapies in the US
14.10. Market Size of AMD in the EU-5
14.10.1. Market Size of Wet AMD in the EU-5
14.10.1.1. Total Market Size of Wet AMD in the EU-5
14.10.1.2. Total Market Size of Wet AMD by Therapies in the EU-5
14.10.2. Market Size of Dry AMD in the EU-5
14.10.2.1. Total Market Size of Dry AMD in the EU-5
14.10.2.2. Total Market Size of Dry AMD by Therapies in the EU-5
14.10.3. Germany
14.10.3.1. Market Size of Wet AMD in Germany
14.10.3.1.1. Total Market Size of Wet AMD in Germany
14.10.3.1.2. Total Market Size of Wet AMD by Therapies in Germany
14.10.3.2. Market Size of Dry AMD in Germany
14.10.3.2.1. Total Market Size of Dry AMD in Germany
14.10.3.2.2. Total Market Size of Dry AMD by Therapies in Germany
14.10.4. France
14.10.4.1. Market Size of Wet AMD in France
14.10.4.1.1. Total Market Size of Wet AMD in France
14.10.4.1.2. Total Market Size of Wet AMD by Therapies in France
14.10.4.2. Market Size of Dry AMD in France
14.10.4.2.1. Total Market Size of Dry AMD in France
14.10.4.2.2. Total Market Size of Dry AMD by Therapies in France
14.10.5. Italy
14.10.5.1. Market Size of Wet AMD in Italy
14.10.5.1.1. Total Market Size of Wet AMD in Italy
14.10.5.1.2. Total Market Size of Wet AMD by Therapies in Italy
14.10.5.2. Market Size of Dry AMD in Italy
14.10.5.2.1. Total Market Size of Dry AMD in Italy
14.10.5.2.2. Total Market Size of Dry AMD by Therapies in Italy
14.10.6. Spain
14.10.6.1. Market Size of Wet AMD in Spain
14.10.6.1.1. Total Market Size of Wet AMD in Spain
14.10.6.1.2. Total Market Size of Wet AMD by Therapies in Spain
14.10.6.2. Market Size of Dry AMD in Spain
14.10.6.2.1. Total Market Size of Dry AMD in Spain
14.10.6.2.2. Total Market Size of Dry AMD by Therapies in Spain
14.10.7. The United Kingdom
14.10.7.1. Market Size of Wet AMD in the United Kingdom
14.10.7.1.1. Total Market Size of Wet AMD in the United Kingdom
14.10.7.1.2. Total Market Size of Wet AMD by Therapies in the United Kingdom
14.10.7.2. Market Size of Dry AMD in the United Kingdom
14.10.7.2.1. Total Market Size of Dry AMD in the United Kingdom
14.10.7.2.2. Total Market Size of Dry AMD by Therapies in the United Kingdom
14.11. Market Size of AMD in Japan
14.11.1. Market Size of Wet AMD in Japan
14.11.1.1. Total Market Size of Wet AMD in Japan
14.11.1.2. Total Market Size of Wet AMD by Therapies in Japan
14.11.2. Market Size of Dry AMD in Japan
14.11.2.1. Total Market Size of Dry AMD in Japan
14.11.2.2. Total Market Size of Dry AMD by Therapies in Japan
15. Key Opinion Leaders' Views
16. Market Drivers
16.1. Market Drivers of Wet AMD
16.2. Market Drivers of Dry AMD
17. Market Barriers
17.1. Market Barriers of Wet AMD
17.2. Market Barriers of Dry AMD
18. SWOT Analysis
18.1. SWOT Analysis of Wet AMD
18.2. SWOT Analysis of Dry AMD
19. Market Access and Reimbursement of Wet AMD
20. Unmet Needs
20.1. Unmet Needs of Wet AMD
20.2. Unmet Needs of Dry AMD
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. Publisher Capabilities
23. Disclaimer
24. About the PublisherList of Tables
Table 1: Summary of Wet AMD, Market, Epidemiology, and Key Events (2019-2032)
Table 2: Summary of Dry AMD Market, Epidemiology, and Key Events (2019-2032)
Table 3: Key Events of Wet AMD
Table 4: Key Events of Dry AMD
Table 5: AREDS Risk Factor Scoring System
Table 6: Drusen Classification
Table 7: Properties of Anti-VEGF Agents
Table 8: Total Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Table 9: Type-specific Diagnosed Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Table 10: Total Prevalent Cases of AMD in the United States, in 000’ (2019-2032)
Table 11: Total Diagnosed Cases of AMD in the United States, in 000’ (2019-2032)
Table 12: Type-specific Cases of AMD in the United States, in 000’ (2019-2032)
Table 13: Total Age-specific Cases of Wet AMD in the United States, in 000’ (2019-2032)
Table 14: Total Diagnosed cases of Dry AMD by Age Distribution in the US in, 000’ (2019-2032)
Table 15: Total Diagnosed Dry AMD Cases by Stages in the US, 000’ (2019-2032)
Table 16: Total Geographic Atrophy Cases by Visual Impairment in the US, 000’ (2019-2032)
Table 17: Total Prevalent Cases of AMD in the EU-5, in 000’ (2019-2032)
Table 18: Total Diagnosed Cases of AMD in the EU-5, in 000’ (2019-2032)
Table 19: Type-specific Cases of AMD in the EU-5, in 000’ (2019-2032)
Table 20: Total Age-specific Cases of Wet AMD in the EU-5, in 000’ (2019-2032)
Table 21: Total Diagnosed cases of Dry AMD by Age Distribution in EU5, 000’ (2019-2032)
Table 22: Total Diagnosed Dry AMD Cases by Stages in EU5, 000’ (2019-2032)
Table 23: Total Geographic Atrophy Cases by Visual Impairment in EU5, 000’ (2019-2032)
Table 24: Total Prevalent Cases of AMD in Germany, in 000’ (2019-2032)
Table 25: Total Diagnosed Cases of AMD in Germany, in 000’ (2019-2032)
Table 26: Type-specific Cases of AMD in Germany, in 000’ (2019-2032)
Table 27: Total Age-specific Cases of Wet AMD in Germany, in 000’ (2019-2032)
Table 28: Total Diagnosed cases of Dry AMD by Age Distribution in Germany, in 000’ (2019-2032)
Table 29: Total Diagnosed Dry AMD Cases by Stages in Germany, in 000’ (2019-2032)
Table 30: Total Geographic Atrophy Cases by Visual Impairment in Germany, in 000’ (2019-2032)
Table 31: Total Prevalent Cases of AMD in France, in 000’ (2019-2032)
Table 32: Total Diagnosed Cases of AMD in France, in 000’ (2019-2032)
Table 33: Type-specific Cases of AMD in France, in 000’ (2019-2032)
Table 34: Total Age-specific Cases of Wet AMD in France, in 000’ (2019-2032)
Table 35: Total Diagnosed cases of Dry AMD by Age Distribution in France, in 000’ (2019-2032)
Table 36: Total Diagnosed Dry AMD Cases by Stages in France, in 000’ (2019-2032)
Table 37: Total Geographic Atrophy Cases by Visual Impairment in France, in 000’ (2019-2032)
Table 38: Total Prevalent Cases of AMD in Italy, in 000’ (2019-2032)
Table 39: Total Diagnosed Cases of AMD in Italy, in 000’ (2019-2032)
Table 40: Type-specific Cases of AMD in Italy, in 000’ (2019-2032)
Table 41: Total Age-specific Cases of Wet AMD in Italy, in 000’ (2019-2032)
Table 42: Total Diagnosed cases of Dry AMD by Age Distribution in Italy, in 000’ (2019-2032)
Table 43: Total Diagnosed Dry AMD Cases by Stages in Italy, in 000’ (2019-2032)
Table 44: Total Geographic Atrophy Cases by Visual Impairment in Italy, in 000’ (2019-2032)
Table 45: Total Prevalent Cases of AMD in Spain, in 000’ (2019-2032)
Table 46: Total Diagnosed Cases of AMD in Spain, in 000’ (2019-2032)
Table 47: Type-specific Cases of AMD in Spain, in 000’ (2019-2032)
Table 48: Total Age-specific Cases of Wet AMD in Spain, in 000’ (2019-2032)
Table 49: Total Diagnosed cases of Dry AMD by Age Distribution in Spain, in 000’ (2019-2032)
Table 50: Total Diagnosed Dry AMD Cases by Stages in Spain, in 000’ (2019-2032)
Table 51: Total Geographic Atrophy Cases by Visual Impairment in Spain, in 000’ (2019-2032)
Table 52: Total Prevalent Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Table 53: Total Diagnosed Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Table 54: Type-specific Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Table 55: Total Age-specific Cases of Wet AMD in the United Kingdom, in 000’ (2019-2032)
Table 56: Total Diagnosed cases of Dry AMD by Age Distribution in the United Kingdom, in 000’ (2019-2032)
Table 57: Total Diagnosed Dry AMD Cases by Stages in the United Kingdom, in 000’ (2019-2032)
Table 58: Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom, in 000’ (2019-2032)
Table 59: Total Prevalent Cases of AMD in Japan, in 000’ (2019-2032)
Table 60: Total Diagnosed Cases of AMD in Japan, in 000’ (2019-2032)
Table 61: Type-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Table 62: Total Age-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Table 63: Total Diagnosed cases of Dry AMD by Age Distribution in Japan, 000’ (2019-2032)
Table 64: Total Diagnosed Dry AMD Cases by Stages in Japan, 000’ (2019-2032)
Table 65: Total Geographic Atrophy Cases by Visual Impairment in Japan, 000’ (2019-2032)
Table 66: Comparison of Marketed Drugs for Wet AMD
Table 67: Eylea, Clinical Trial Description, 2022
Table 68: Beovu, Clinical Trial Description, 2022
Table 69: Lucentis, Clinical Trial Description, 2022
Table 70: Faricimab, Clinical Trial Description, 2022
Table 71: Susvimo, Clinical Trial Description, 2022
Table 72: Comparison of Emerging Drugs Under Development for Wet AMD (1/2)
Table 73: Comparison of Emerging Drugs Under Development for Wet AMD (2/2)
Table 74: OPT-302, Clinical Trial Description, 2022
Table 75: KSI-301, Clinical Trial Description, 2022
Table 76: RGX-314, Clinical Trial Description, 2022
Table 77: AKST4290, Clinical Trial Description, 2022
Table 78: Sunitinib Malate, Clinical Trial Description, 2022
Table 79: RBM-007, Clinical Trial Description, 2022
Table 80: Lytenava, Clinical Trial Description, 2022
Table 81: UBX1325, Clinical Trial Description, 2022
Table 82: PAN-90806, Clinical Trial Description, 2022
Table 83: CLS-AX Clinical Trial Description, 2022
Table 84: Comparison of emerging drugs under development
Table 85: Danicopan, Clinical Trial Description, 2022
Table 86: EG-301, Clinical Trial Description, 2022
Table 87: RG6147, Clinical Trial Description, 2022
Table 88: ALK-001, Clinical Trial Description, 2022
Table 89: Elamipretide, Clinical Trial Description, 2022
Table 90: OpRegen, Clinical Trial Description, 2022
Table 91: CPCB-RPE1, Clinical Trial Description, 2022
Table 92: Luminate, Clinical Trial Description, 2022
Table 93: ANX007, Clinical Trial Description, 2022
Table 94: NGM621, Clinical Trial Description, 2022
Table 95: LNP023, Clinical Trial Description, 2022
Table 96: IONIS-FB-LRx, Clinical Trial Description, 2022
Table 97: Pegcetacoplan, Clinical Trial Description, 2022
Table 98: Zimura, Clinical Trial Description, 2022
Table 99: GT005, Clinical Trial Description, 2022
Table 100: RPESC-RPE-4W, Clinical Trial Description, 2022
Table 101: GEM103, Clinical Trial Description, 2022
Table 102: Key Market Forecast Assumptions for OPT-302
Table 103: Key Market Forecast Assumptions for KSI-301
Table 104: Key Market Forecast Assumptions for RGX-314
Table 105: Key Market Forecast Assumptions for AKST4290
Table 106: Key Market Forecast Assumptions for GB-102
Table 107: Key Market Forecast Assumptions for RBM-007
Table 108: Key Market Forecast Assumptions for Lytenava (bevacizumab-vikg)
Table 109: Key Market Forecast Assumptions for Vabysmo (Faricimab)
Table 110: Key Market Forecast Assumptions for Susvimo (ranibizumab injection)
Table 111: Key Market Forecast Assumptions for Pegcetacoplan
Table 112: Key Market Forecast Assumptions for Zimura
Table 113: Key Market Forecast Assumptions for Elamipretide
Table 114: Key Market Forecast Assumptions for Luminate
Table 115: Key Market Forecast Assumptions for RG6147
Table 116: Key Market Forecast Assumptions for IONIS-FB-LRx
Table 117: Key Market Forecast Assumptions for OpRegen
Table 118: Key Market Forecast Assumptions for CPCB-RPE1
Table 119: Key Market Forecast Assumptions for Danicopan
Table 120: Key Market Forecast Assumptions for ANX007
Table 121: Key Market Forecast Assumptions for NGM621
Table 122: Key Market Forecast Assumptions for GT005
Table 123: 7MM Market Size of Wet AMD in USD Million (2019-2032)
Table 124: 7MM Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 125: Market Size of Dry AMD in the 7MM in USD million (2019-2032)
Table 126: Market Size of Dry AMD by Current and Emerging Therapies in the US, in USD million (2019-2032)
Table 127: The United States Market Size of Wet AMD in USD Million (2019-2032)
Table 128: The United States Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 129: Market Size of Dry AMD in the US, USD million (2019-2032)
Table 130: Market Size of Dry AMD by Current and Emerging Therapies in the US, in USD million (2019-2032)
Table 131: Total Market Size of Wet AMD in the EU-5, USD Millions (2019-2032)
Table 132: Germany Market Size of Wet AMD in USD Million (2019-2032)
Table 133: Germany Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 134: France Market Size of Wet AMD in USD Million (2019-2032)
Table 135: France Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 136: Italy Market Size of Wet AMD in USD Million (2019-2032)
Table 137: Italy Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 138: Spain Market Size of Wet AMD in USD Million (2019-2032)
Table 139: Spain Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 140: The UK Market Size of Wet AMD in USD Million (2019-2032)
Table 141: The UK Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 142: EU-5 Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 143: EU5 Market Size of Dry AMD in USD million (2019-2032)
Table 144: Market Size of Dry AMD in Germany, in USD million (2019-2032)
Table 145: Market Size of Dry AMD by Current and Emerging Therapies in Germany, in USD million (2019-2032)
Table 146: Market Size of Dry AMD in France, in USD million (2019-2032)
Table 147: Market Size of Dry AMD by Current and Emerging Therapies in France, in USD million (2019-2032)
Table 148: Market Size of Dry AMD in Italy, in USD million (2019-2032)
Table 149: Market Size of Dry AMD by Current and Emerging Therapies in Italy, in USD million (2019-2032)
Table 150: Market Size of Dry AMD in Spain, in USD million (2019-2032)
Table 151: Market Size of Dry AMD by Current and Emerging Therapies in Spain, in USD million (2019-2032)
Table 152: Market Size of Dry AMD in the UK, in USD million (2019-2032)
Table 153: Market Size of Dry AMD by Current and Emerging Therapies in the UK, in USD million (2019-2032)
Table 154: Market Size of Dry AMD by Current and Emerging Therapies in EU5, in USD million (2019-2032)
Table 155: Japan Market Size of Wet AMD in USD Million (2019-2032)
Table 156: Japan Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Table 157: Market Size of Dry AMD in Japan, USD million (2019-2032)
Table 158: Market Size of Dry AMD by Current and Emerging Therapies in Japan, in USD million (2019-2032)
Table 159: To appraise the clinical and cost-effectiveness of faricimab within its marketing authorization for treating wet age-related macular degeneration.
Table 160: Aflibercept solution for injection for treating wet age-related macular degeneration
List of Figures
Figure 1: Dry and wet AMD
Figure 2: Cellular Senescence contributing to AMD
Figure 3: Inflammation in AMD
Figure 4: AMD Treatment Guidelines
Figure 5: Total Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Figure 6: Type-specific Diagnosed Prevalent Cases of AMD in the 7MM, in 000’ (2019-2032)
Figure 7: Total Prevalent Cases of AMD in the United States, in 000’ (2019-2032)
Figure 8: Total Diagnosed Cases of AMD in the United States, in 000’ (2019-2032)
Figure 9: Type-specific Cases of AMD in the United States, in 000’ (2019-2032)
Figure 10: Total Age-specific Cases of Wet AMD in the United States, in 000’ (2019-2032)
Figure 11: Total Diagnosed cases of Dry AMD by Age Distribution in the US in, 000’ (2019-2032)
Figure 12: Total Diagnosed Dry AMD Cases by Stages in the US, 000’ (2019-2032)
Figure 13: Total Geographic Atrophy Cases by Visual Impairment in the US, 000’ (2019-2032)
Figure 14: Total Prevalent Cases of AMD in the EU-5, in 000’ (2019-2032)
Figure 15: Total Diagnosed Cases of AMD in the EU-5, in 000’ (2019-2032)
Figure 16: Type-specific Cases of AMD in the EU-5, in 000’ (2019-2032)
Figure 17: Total Age-specific Cases of Wet AMD in the EU-5, in 000’ (2019-2032)
Figure 18: Total Diagnosed cases of Dry AMD by Age Distribution in EU5, 000’ (2019-2032)
Figure 19: Total Diagnosed Dry AMD Cases by Stages in EU5, 000’ (2019-2032)
Figure 20: Total Geographic Atrophy Cases by Visual Impairment in EU5, 000’ (2019-2032)
Figure 21: Total Prevalent Cases of AMD in Germany, in 000’ (2019-2032)
Figure 22: Total Diagnosed Cases of AMD in Germany, in 000’ (2019-2032)
Figure 23: Type-specific Cases of AMD in Germany, in 000’ (2019-2032)
Figure 24: Total Age-specific Cases of Wet AMD in Germany, in 000’ (2019-2032)
Figure 25: Total Diagnosed cases of Dry AMD by Age Distribution in Germany, in 000’ (2019-2032)
Figure 26: Total Diagnosed Dry AMD Cases by Stages in Germany, in 000’ (2019-2032)
Figure 27: Total Geographic Atrophy Cases by Visual Impairment in Germany, in 000’ (2019-2032)
Figure 28: Total Prevalent Cases of AMD in France, in 000’ (2019-2032)
Figure 29: Total Diagnosed Cases of AMD in France, in 000’ (2019-2032)
Figure 30: Type-specific Cases of AMD in France, in 000’ (2019-2032)
Figure 31: Total Age-specific Cases of Wet AMD in France, in 000’ (2019-2032)
Figure 32: Total Diagnosed cases of Dry AMD by Age Distribution in France, in 000’ (2019-2032)
Figure 33: Total Diagnosed Dry AMD Cases by Stages in France, in 000’ (2019-2032)
Figure 34: Total Geographic Atrophy Cases by Visual Impairment in France, in 000’ (2019-2032)
Figure 35: Total Prevalent Cases of AMD in Italy, in 000’ (2019-2032)
Figure 36: Total Diagnosed Cases of AMD in Italy, in 000’ (2019-2032)
Figure 37: Type-specific Cases of AMD in Italy, in 000’ (2019-2032)
Figure 38: Total Age-specific Cases of Wet AMD in Italy, in 000’ (2019-2032)
Figure 39: Total Diagnosed cases of Dry AMD by Age Distribution in Italy, in 000’ (2019-2032)
Figure 40: Total Diagnosed Dry AMD Cases by Stages in Italy, in 000’ (2019-2032)
Figure 41: Total Geographic Atrophy Cases by Visual Impairment in Italy, in 000’ (2019-2032)
Figure 42: Total Prevalent Cases of AMD in Spain, in 000’ (2019-2032)
Figure 43: Total Diagnosed Cases of AMD in Spain, in 000’ (2019-2032)
Figure 44: Type-specific Cases of AMD in Spain, in 000’ (2019-2032)
Figure 45: Total Age-specific Cases of Wet AMD in Spain, in 000’ (2019-2032)
Figure 46: Total Diagnosed cases of Dry AMD by Age Distribution in Spain, in 000’ (2019-2032)
Figure 47: Total Diagnosed Dry AMD Cases by Stages in Spain, in 000’ (2019-2032)
Figure 48: Total Geographic Atrophy Cases by Visual Impairment in Spain, in 000’ (2019-2032)
Figure 49: Total Prevalent Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Figure 50: Total Diagnosed Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Figure 51: Type-specific Cases of AMD in the United Kingdom, in 000’ (2019-2032)
Figure 52: Total Age-specific Cases of Wet AMD in the United Kingdom, in 000’ (2019-2032)
Figure 53: Total Diagnosed cases of Dry AMD by Age Distribution in the United Kingdom, in 000’ (2019-2032)
Figure 54: Total Diagnosed Dry AMD Cases by Stages in the United Kingdom, in 000’ (2019-2032)
Figure 55: Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom, in 000’ (2019-2032)
Figure 56: Total Prevalent Cases of AMD in Japan, in 000’ (2019-2032)
Figure 57: Total Diagnosed Cases of AMD in Japan, in 000’ (2019-2032)
Figure 58: Type-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Figure 59: Total Age-specific Cases of Wet AMD in Japan, in 000’ (2019-2032)
Figure 60: Total Diagnosed cases of Dry AMD by Age Distribution in Japan, 000’ (2019-2032)
Figure 61: Total Diagnosed Dry AMD Cases by Stages in Japan, 000’ (2019-2032)
Figure 62: Total Geographic Atrophy Cases by Visual Impairment in Japan, 000’ (2019-2032)
Figure 63: 7MM Market Size of Wet AMD in USD Million (2019-2032)
Figure 64: 7MM Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 65: Market Size of Dry AMD in the 7MM in USD million (2019-2032)
Figure 66: Market Size of Dry AMD by Current and Emerging Therapies in the US, in USD million (2019-2032)
Figure 67: The United States Market Size of Wet AMD in USD Million (2019-2032)
Figure 68: The United States Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 69: Market Size of Dry AMD in the US, USD million (2019-2032)
Figure 70: Market Size of Dry AMD by Current and Emerging Therapies in the US, in USD million (2019-2032)
Figure 71: Total Market Size of Wet AMD in the EU-5, USD Millions (2019-2032)
Figure 72: Germany Market Size of Wet AMD in USD Million (2019-2032)
Figure 73: Germany Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 74: France Market Size of Wet AMD in USD Million (2019-2032)
Figure 75: France Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 76: Italy Market Size of Wet AMD in USD Million (2019-2032)
Figure 77: Italy Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 78: Spain Market Size of Wet AMD in USD Million (2019-2032)
Figure 79: Spain Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 80: The UK Market Size of Wet AMD in USD Million (2019-2032)
Figure 81: The UK Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 82: EU-5 Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 83 EU5 Market Size of Dry AMD in USD million (2019-2032)
Figure 84: Market Size of Dry AMD in Germany, in USD million (2019-2032)
Figure 85: Market Size of Dry AMD by Current and Emerging Therapies in Germany, in USD million (2019-2032)
Figure 86: Market Size of Dry AMD in France, in USD million (2019-2032)
Figure 87: Market Size of Dry AMD by Current and Emerging Therapies in France, in USD million (2019-2032)
Figure 88: Market Size of Dry AMD in Italy, in USD million (2019-2032)
Figure 89: Market Size of Dry AMD by Current and Emerging Therapies in Italy, in USD million (2019-2032)
Figure 90: Market Size of Dry AMD in Spain, in USD million (2019-2032)
Figure 91: Market Size of Dry AMD by Current and Emerging Therapies in Spain, in USD million (2019-2032)
Figure 92: Market Size of Dry AMD in the UK, in USD million (2019-2032)
Figure 93: Market Size of Dry AMD by Current and Emerging Therapies in the UK, in USD million (2019-2032)
Figure 94: Market Size of Dry AMD by Current and Emerging Therapies in EU5, in USD million (2019-2032)
Figure 95: Japan Market Size of Wet AMD in USD Million (2019-2032)
Figure 96: Japan Market Size of Wet AMD by Therapies in USD Million (2019-2032)
Figure 97: Market Size of Dry AMD in Japan, USD million (2019-2032)
Figure 98: Market Size of Dry AMD by Current and Emerging Therapies in Japan, in USD million (2019-2032)
Figure 99: Market Drivers of Wet AMD
Figure 100: Market Drivers of Dry AMD
Figure 101: Market Barriers of Wet AMD
Figure 102: Market Barriers of Dry AMD
Figure 103: Unmet Needs of Wet AMD
Figure 104: Unmet Needs of Dry AMD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexion Pharmaceuticals
- Alkahest Inc
- Alkeus Pharmaceuticals
- Allegro Ophthalmics
- Annexon Biosciences
- Apellis Pharmaceuticals
- AstraZeneca
- CellCure Neurosciences
- Clearside Biomedical
- Evergreen Therapeutics
- Gemini Therapeutics
- Graybug Vision
- Gyroscope Therapeutics and Novartis
- Ionis Pharmaceuticals
- Iveric Bio
- Kodiak Sciences Inc.
- Luxa Biotechnology
- NGM Biopharmaceuticals
- Novartis
- Opthea Limited
- Outlook Therapeutics, Inc.
- PanOptica, Inc.
- Regenerative Patch Technologies
- Regeneron Pharmaceuticals
- REGENXBIO
- Ribomic USA Inc
- Roche
- Stealth BioTherapeutics
- Unity Biotechnology, Inc
